F. Hoffmann-La Roche Ag

The Institute of Cancer Research: Royal Cancer Hospital

Paul John Goldsmith

Stephen Joseph Shuttleworth

Timothy Colin Hancox

Stephen Colin Price

Stewart James Baker

Neil Anthony Pegg

Adrian Folkes

Irina Chuckowree

Sukhjit Sohal

Elsa Amandine Dechaux

Sukhjit Sohai

Edward Mcdonald

Jonathan Martin Large

Thienopyrimidines of formula (Ia) or (Ib): wherein R-Rhave any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Pharmaceutical compounds

Thienopyrimidines of formula (Ia) or (Ib): wherein R-Rhave any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Pyrimidine derivatives as PI3K inhibitors

Fused pyrimidines of formula (I): wherein A, n, R, R, and Rhave any of the values defined herein and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Substituted thieno- and furano- fused pyrimidines as PI3K inhibitors

Growing community of inventors

Slough, United Kingdom

Paul John Goldsmith